A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-Small-Cell lung cancer

R. J. Kelly, A. Thomas, A. Rajan, G. Chun, A. Lopez-Chavez, E. Szabo, S. Spencer, C. A. Carter, U. Guha, S. Khozin, S. Poondru, C. Van Sant, A. Keating, S. M. Steinberg, W. Figg, G. Giaccone^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review